Back to results
US 8,507,017 B2Granted
Method for decreasing nicotine and other substance use in humans
AssigneeArizona Health Consulting Group, LLC
InventorJie Wu
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeArizona Health Consulting Group, LLC
InventorJie Wu
Estimating the term…
A method for decreasing nicotine and other substance use in humans is disclosed. Tetrahydroberberine (THB) and its analogs, l-Tetrahydropalmatine (l-THP) and l-Stepholidine (l-SPD), are present in and can be isolated from several plants in the Magnoliidae superorder. According to the disclosed method, THB and its analogs are used to block nicotine-induced DA release, and modulate heterologous or homoeric expression of human nicotinic acetylcholine receptors (nAChR) in humans. Specifically, THB exhibits bi-directory modulation of α4β2-nAChR-mediated currents induced by nicotine. THB also shows predominant inhibition on homologously expressed α7-nAChR function. Thus, according to the disclosed method, THB is used to simultaneous blockade midbrain DA system function, the brain reward center, and neuronal α4β2- and α7-nAChR function, the major nicotine targets in the brain. Therefore, THB and its analogs serve as a novel class of natural compounds to decrease nicotine dependence in humans. Furthermore other substances, such as alcohol, cocaine, and opiates, also operate by triggering the brain reward center, resulting in a cycle of substance or alcohol abuse. THB and its analogs can be used to decrease use of substances such as alcohol, cocaine, and opiates. Finally, because THB and its analogs are DA antagonists, THB and its analogs can also be used as a treatment for Parkinson's Disease, Alzheimer's Disease and Schizophrenia.
A method of attenuating nicotine withdrawal by desensitizing nicotinic acetylcholine receptors comprising the step of administering an effective amount of tetrahydroberberine or analog thereof to a subject having or at risk of having nicotine withdrawal such that nicotinic acetylcholine receptors are desensitized, wherein the analog is selected from the group consisting of l-tetrahydropalmatine and l-stepholidine.
A method of reducing sensitization to nicotine by attenuating nicotine-induced dopamine release by nicotinic acetylcholine receptors comprising the step of administering an effective amount of tetrahydroberberine or analog thereof to a subject having or at risk of having sensitization to nicotine such that nicotine-induced dopamine release is attenuated, wherein the analog is selected from the group consisting of l-tetrahydropalmatine and l-stepholidine.
A method of attenuating nicotinic acetylcholine receptors in a subject in need thereof comprising the step of administering an effective amount of tetrahydroberberine or analog thereof and an effective amount of nicotine to the subject, wherein the analog of tetrahydroberberine is selected from the group consisting of l-tetrahydropalmatine and l-stepholidine;
A method of attenuating nicotinic acetylcholine receptors in a subject in need thereof comprising the step of administering an effective amount of tetrahydroberberine or analog thereof and an effective amount of nicotine to the subject such that nicotinic acetylcholine receptors are desensitized, wherein the analog of tetrahydroberberine is selected from the group consisting of l-tetrahydropalmatine and l-stepholidine;
A method of treatment of nicotine withdrawal symptoms in a subject in need thereof comprising the step of administering an effective amount of tetrahydroberberine or analog thereof and an effective amount of nicotine to the subject such that nicotinic acetylcholine receptors efficacy is enhanced, wherein the analog of tetrahydroberberine is selected from the group consisting of l-tetrahydropalmatine and l-stepholidine;
Dependencies are inferred from the claim text.